Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of sintilimab plus doxorubicin in metastatic or unresectable soft tissue sarcoma
ChiCTR1900027009Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Dec 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and doxorubicin in soft tissue sarcoma (STS), sponsored by Henan Cancer Hospital. Primary endpoint: major pathological response. Planned start Dec 2019; status: not yet recruiting.
02
Drugs
sintilimabdoxorubicin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR1900027009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027009.